Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147

Authors

Suresh G. Nair MD, Lehigh Valley Health NetworkFollow
Richard M. GoldbergFollow
Daniel J. SargentFollow
Stephen N. ThibodeauFollow
Margaret R. MahoneyFollow
Anthony F. Sheilds
Emily ChanFollow
Sharlene GillFollow
Morton S. KahlenbergFollow
Steven R. Alberts MD, MPHFollow

Publication/Presentation Date

2010

Published In/Presented At

Nair, S., Goldberg, R., Sargent, D., Thibodeau, S., Mahoney, M., Shields, A., Chan, E., Gill, S., Kahlenberg, S., & Alberts, S. (2010). Adjuvant mFOLFOX6+/- cetuximab in patients with KRAS mutant resected stage III colon cancer: NCCTG intergroup phase III trial N0147. Presentation presented at: 2010 ASCO Annual Meeting,

Disciplines

Medical Sciences | Medicine and Health Sciences

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Department of Medicine Faculty

Document Type

Presentation